Reglan exclusivity
Executive Summary
Robins' I.V. formulation of metoclopramide lost exclusive labeling for chemotherapy- and cisplatin-induced emesis and diabetic gastroparesis on Sept. 24, 1986. "The Pink Sheet" (Oct. 20, "In Brief") erroneously said exclusivity for the indications did not expire until December 1987. Robins did, however, recently obtain a patent covering the method of controlling emesis caused by cisplatin and cancer chemotherapy. That patent, which expires in August 2002, is the only patent in force on Reglan.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.